KREBSBIO61.00

Krebs Biochemicals and Industries Limited

· Pharma & Health
₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹132 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity16.5518.4210.4010.40
Return on Assets-11.07-15.94-10.37-10.37
Return on Capital Employed-13.31-33.15-23.66-23.66
Return on Invested Capital-20.91-32.99-19.16-14.44
Margins
EBITDA Margin-17.30-34.70-22.97-10.05
Operating Margin-30.72-50.14-50.03-50.03
Incremental Operating Margin87.61-50.28
Pretax Margin-39.13-62.16-71.35-55.85
Net Income Margin-39.13-62.20-71.35-55.85
FCF Margin-10.93-30.07-24.95-24.95
Additional
Effective Tax Rate0.00-0.060.00-0.00
Sustainable Growth Rate16.5518.4210.4010.40
Incremental Operating Margin %87.61-50.28194.66
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.